A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Hu, Guangzhen ^a   Witzig, Thomas E ^a   Gupta, Mamta ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; LUCIFERASE; LYSINE; METHIONINE; STAT3 PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN DEPHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STAT3 GENE; STOP CODON; TRANSCRIPTION INITIATION; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

AMINO ACID SEQUENCE; B-LYMPHOCYTES; CELL LINE, TUMOR; EXONS; GENES, REPORTER; GENETIC VECTORS; HUMANS; JANUS KINASE 2; LENTIVIRUS; LUCIFERASES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84879816714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067851     Document Type: Article

References (25)

1. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, et al. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111: 3701-3713.
2. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, et al. (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111: 1515-1523.
3. Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, et al. (2012) Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood 120: 4400-4406.
4. Wu ZL, Song YQ, Shi YF, Zhu J, (2011) High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. Journal of hematology & oncology 4: 31.
5. Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, et al. (2011) STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer research 71: 3182-3188.
6. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ, (2011) Stat3 signaling in acute myeloid leukemia: ligand-dependent and-independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117: 5701-5709.
7. Ashizawa T, Miyata H, Ishii H, Oshita C, Matsuno K, et al. (2011) Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. International journal of oncology 38: 1245-1252.
8. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, et al. (2012) Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 119: 2844-2853.
9. Witzig TE, Price-Troska TL, Stenson MJ, Gupta M, (2013) Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained. Leukemia & lymphoma 54: 397-399.
10. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, et al. (2012) STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120: 3048-3057.
11. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, et al. (2012) Somatic STAT3 mutations in large granular lymphocytic leukemia. The New England journal of medicine 366: 1905-1913.
12. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303.
13. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, et al. (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy of Sciences of the United States of America 109: 3879-3884.
14. Eyckerman S, Broekaert D, Verhee A, Vandekerckhove J, Tavernier J, (2000) Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor. FEBS letters 486: 33-37.
15. Dumoutier L, de Meester C, Tavernier J, Renauld JC, (2009) New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. The Journal of biological chemistry 284: 26377-26384.
16. Gupta M, Dillon SR, Ziesmer SC, Feldman AL, Witzig TE, et al. (2009) A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood 113: 5206-5216.
17. Ma J, Zhang T, Novotny-Diermayr V, Tan AL, Cao X, (2003) A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation. The Journal of biological chemistry 278: 29252-29260.
18. Sato N, Tsuruma R, Imoto S, Sekine Y, Muromoto R, et al. (2005) Nuclear retention of STAT3 through the coiled-coil domain regulates its activity. Biochemical and biophysical research communications 336: 617-624.
19. Ma J, Cao X, (2006) Regulation of Stat3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cellular signalling 18: 1117-1126.
20. Zhang T, Kee WH, Seow KT, Fung W, Cao X, (2000) The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Molecular and cellular biology 20: 7132-7139.
21. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, et al. (2008) TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 22: 1790-1792.
22. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 789-796.
23. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13: 311-320.
24. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, et al. (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. Nature genetics 43: 830-837.
25. Kumanovics A, Perkins SL, Gilbert H, Cessna MH, Augustine NH, et al. (2010) Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation. Journal of clinical immunology 30: 886-893.